These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17417795)

  • 21. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
    Koh ES; Sun A; Tran TH; Tsang R; Pintilie M; Hodgson DC; Wells W; Heaton R; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):223-8. PubMed ID: 16904523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal-change nephrotic syndrome preceding Hodgkin lymphoma by 5 years with expression of tumor necrosis factor alpha in Hodgkin-Reed-Sternberg cells.
    Nakayama S; Yokote T; Kobayashi K; Hirata Y; Akioka T; Hiraoka N; Oka S; Miyoshi T; Takubo T; Tsuji M; Hanafusa T
    Hum Pathol; 2010 Aug; 41(8):1196-9. PubMed ID: 20624522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.
    Rassidakis GZ; Medeiros LJ; Viviani S; Bonfante V; Nadali GP; Vassilakopoulos TP; Mesina O; Herling M; Angelopoulou MK; Giardini R; Chilosi M; Kittas C; McLaughlin P; Rodriguez MA; Romaguera J; Bonadonna G; Gianni AM; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
    J Clin Oncol; 2002 Mar; 20(5):1278-87. PubMed ID: 11870170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
    Tzankov A; Krugmann J; Fend F; Fischhofer M; Greil R; Dirnhofer S
    Clin Cancer Res; 2003 Apr; 9(4):1381-6. PubMed ID: 12684408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
    Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
    Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.
    Rassidakis GZ; Medeiros LJ; McDonnell TJ; Viviani S; Bonfante V; Nadali G; Vassilakopoulos TP; Giardini R; Chilosi M; Kittas C; Gianni AM; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
    Clin Cancer Res; 2002 Feb; 8(2):488-93. PubMed ID: 11839668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ten-year outcomes of lymphogranulomatosis treatment according to the protocol MOPP-ABVD+radiotherapy].
    Pivnik AV; Rastrigin NA; Moiseeva TN; Lutsenko IN; Dudarova RG; Shavlokhov VS; Efimov IV; Kozhurin SV; Shitareva IV; Gemdzhian EG; Tsyba NN; Kolosova LIu; Melikian AL; Skidan NI; Pan'shin GA; Sotnikov VM; Dotsenko PV; Nechistiuk AV
    Ter Arkh; 2006; 78(8):57-62. PubMed ID: 17078219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma.
    Passam FH; Alexandrakis MG; Kafousi M; Fotinou M; Darivianaki K; Tsirakis G; Roussou PA; Stathopoulos EN; Siafakas NM
    Pathol Res Pract; 2009; 205(1):11-20. PubMed ID: 18950958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: a progress report.
    Sagar TG; Chandra A; Raman SG
    Med Pediatr Oncol; 2003 Jan; 40(1):66-9. PubMed ID: 12426693
    [No Abstract]   [Full Text] [Related]  

  • 31. Hodgkin lymphoma with cutaneous involvement.
    Hsia CC; Howson-Jan K; Rizkalla KS
    Dermatol Online J; 2009 May; 15(5):5. PubMed ID: 19624983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
    Diehl V; Engert A
    Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of Hodgkin lymphoma: the past, present, and future.
    Evens AM; Hutchings M; Diehl V
    Nat Clin Pract Oncol; 2008 Sep; 5(9):543-56. PubMed ID: 18679394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.
    Citak EC; Oguz A; Karadeniz C; Akyurek N
    Pathol Res Pract; 2008; 204(2):89-96. PubMed ID: 18207652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.
    Rassidakis GZ; Medeiros LJ; Vassilakopoulos TP; Viviani S; Bonfante V; Nadali G; Herling M; Angelopoulou MK; Giardini R; Chilosi M; Kittas C; McDonnell TJ; Bonadonna G; Gianni AM; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
    Blood; 2002 Dec; 100(12):3935-41. PubMed ID: 12433696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
    Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
    Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
    Kelley TW; Pohlman B; Elson P; Hsi ED
    Am J Clin Pathol; 2007 Dec; 128(6):958-65. PubMed ID: 18024321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Lymphoma].
    Fu XH; Wang SS; Huang Y; Xiao J; Zhai LZ; Xia ZJ; Huang HQ; Sun XF; Lin TY
    Ai Zheng; 2008 Nov; 27(11):1197-203. PubMed ID: 19000453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.